Close

Add to pipeline

Save Close
You are viewing a limited version of this profile. To access i3's full capabilities.
Precision BioSciences
Save
Company logo (jpg or png)
Parent company
Edit alternate names

Short description

Developer of the proprietary ARCUS Genome Editing method for the treatment of cure genetic diseases and improved crop yield

Founded in 2006
Founded in

Company type Public Public (DTIL)
Company type

Industry Group materials & chemicals

Sector biotechnology

TRL Range 7-8
TRL 1 Basic research
TRL 2 Technology formulation
TRL 3 Applied research
TRL 4 Small scale prototype
TRL 5 Large scale prototype
TRL 6 Prototype system
TRL 7 Demonstration system
TRL 8 First of a kind commercial system
TRL 9 Full commercial application
TRL Range

Ticker

Headquarters Durham, NC Durham, United States
Address
City
State
Zip
Country

Parent Companies

Website

Updated by Jonathan Koch at on 02/02/2018

Traction
  • 0 M&A items
tags
Similar companies
Customers
Save
Add Customer
Date Company
Partnerships
Save
Add Partnership
Date Partner Type
03/10/2014
Agrivida Agrivida
The two companies entered into a trait development collaboration based on precise gene modifications made possible by Precision’s Directed Nuclease EditorTM (DNE) Technology.
View source    
Confirmed by Agrivida
Development Partner
Delete
Investment Rounds
Save

IPO INFORMATION

Date

03/29/2019

IPO status

Listed

IPO Type

IPO

Amount

$126.4M

Initial shares

Ticker symbol

DTIL

Exchange listed

Nasdaq

Prospectus URL

Prospectus

Source URL

Source

Description

the listing values the company at $870 million. \ venBio backs the firm. J.P. Morgan, Goldman Sachs, Jefferies and Barclays are underwriters The IPO will achieve an exit for growth stage agrifood tech investor Pontifax AgTech, which invested $12.5 million in Precision Bioscience’s $110 million Series B in July 2018 and its subsequent pre-IPO convertible note financing in February 2019.

Cancel Save
Add Investment
Date Investors Type Amount
05/11/2015 Baxter Ventures Baxter Ventures , Amgen Amgen , F-Prime Capital Partners F-Prime Capital Partners , Osage University Partners Osage University Partners , RA Capital Management RA Capital Management , Longevity Fund Longevity Fund , venBio Partners venBio Partners , Ziegler Ziegler (8)
Post-money valuation of
Series A $25,600,000
Delete
Click to add IPO information
Products
Save
Add Product
Product image Name Product status Revenue model Cost metrics
You are viewing a limited version of this profile. To access i3's full capabilities.
Back to top

Preload svg text font